Organon Gestion
Gestion contrôle des critères 3/4
Le PDG Organon est Joe Morrissey, nommé en Oct2025, a un mandat de moins d'un an. La rémunération annuelle totale est $ 5.77M, composée du salaire de 14.2% et des bonus 85.8%, y compris les actions et options de la société. détient directement 0.047% des actions de la société, d'une valeur de $ 1.67M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.5 ans et 5.1 ans.
Informations clés
Joe Morrissey
Directeur général
US$5.8m
Rémunération totale
| Pourcentage du salaire du PDG | 14.19% |
| Durée du mandat du directeur général | less than a year |
| Propriété du PDG | 0.05% |
| Durée moyenne d'occupation des postes de direction | 3.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.1yrs |
Mises à jour récentes de la gestion
Recent updates
Seeking Alpha • Jul 14
Organon & Co: Great Odds, Small Prize, Big Penalty
Summary OGN trades at $13.51 against Sun Pharma's $14.00 all-cash offer, leaving 49 cents for new buyers. The 3.7% spread works out to about 6% annualized if the deal closes in early 2027 as planned. If the deal falls through, expect significant downward pressure, and possible return to pre-announcement lows in single digits. We rate OGN a HOLD. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 01
OGN: Takeover Interest And Licensing Pipeline Will Shape Balanced Future Outlook
The analyst fair value estimate for Organon has shifted from $12.00 to $14.00 as analysts factor in updated assumptions on discount rate, revenue growth, profit margins, and potential corporate activity, which are reflected in recent mixed rating changes and takeover commentary. Analyst Commentary Recent research coverage on Organon has been active, with several firms reassessing their views as corporate interest headlines and rating changes come through.
Mise à jour du récit • Jun 17
OGN: Takeover Bid And Mixed Ratings Will Likely Cap Share Upside
The analyst price target for Organon stock has been reset lower to $5.00 from $8.00, with analysts pointing to recent mixed rating actions, changing fair value assumptions, and a revised future P/E outlook as key drivers of the update. Analyst Commentary on Organon Stock Recent research on Organon highlights a split in views, with some firms stepping back from formal ratings and others reassessing potential deal scenarios.
Mise à jour du récit • Jun 03
OGN: Takeover Bid And Mixed Ratings Will Constrain Future Share Upside
Analysts have kept the fair value estimate for Organon steady at $11.25, while making only minor adjustments to discount rate, profit margin and future P/E assumptions as they digest a mix of recent rating changes and takeover speculation. Analyst Commentary Bullish Takeaways Bullish analysts point to reported takeover interest, including discussion of a possible US$15 per share offer, as a reference point that sits above the current fair value estimate of US$11.25, which they view as supportive for the stock's valuation range.Mise à jour du récit • May 07
OGN: Deal Premium And Mixed Ratings Will Limit Further Upside Potential
Analysts have lifted their Organon fair value estimate from $9.00 to $11.25, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E following a mix of recent rating changes, deal interest commentary, and a revised $8.00 price target from Barclays. Analyst Commentary Recent Street research on Organon shows a split view, with some analysts highlighting potential upside drivers and others focusing on execution risks and valuation constraints.Mise à jour du récit • Apr 22
OGN: Takeover Talk Will Likely Leave Shares Struggling Below Deal Level
Analysts have nudged Organon’s target higher, reflecting updated models that incorporate recent takeover interest around $15 per share and sector valuation readthroughs, along with revised assumptions for revenue growth, margins, discount rate, and future P/E. Analyst Commentary Recent research highlights a mix of interest and caution around Organon, with potential deal scenarios and updated sector comparisons feeding into valuation work.Mise à jour du récit • Apr 07
OGN: Raised Price View Will Likely Leave Shares Trapped Near Lows
Analysts have nudged their Organon price target to $8 from $7.50, reflecting updated models after the latest Q4 report and adjusted assumptions around discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research reflects a cautious stance around Organon, even as the price target was adjusted to US$8 from US$7.50 after the latest Q4 report.Mise à jour du récit • Mar 24
OGN: Cautious Q4 Reassessment Will Likely Keep Shares Anchored Near Lows
Analysts have nudged their price target on Organon up to $8 from $7.50, reflecting updated models after the recent Q4 report and a fresh look at the company’s fundamentals. Analyst Commentary Bearish analysts are treating the latest price target move as a fine tuning of a cautious view rather than a shift in conviction.Mise à jour du récit • Mar 10
OGN: Refreshed Earnings Assumptions And M&A Interest Will Support Future Repricing
Analysts have trimmed their fair value estimate for Organon to $9.00, while Barclays lifted its price target to $8.00 from $7.50 after updating its model following the Q4 report, prompting a reassessment of growth, margins and future P/E assumptions in our narrative update. Analyst Commentary Recent Street research reflects a cautious stance on Organon, even as some price targets are adjusted following the Q4 update.Mise à jour du récit • Feb 24
OGN: Potential Takeover Interest Will Drive Future Upside Opportunity
Analysts have trimmed their price target on Organon from $18.00 to $12.00, citing updated assumptions that include a revised fair value estimate, a slightly higher discount rate, a modestly adjusted revenue growth outlook, a lower projected profit margin, and a reduced future P/E multiple. What's in the News Organon issued earnings guidance for full year 2026, targeting approximately US$6.2b in revenue, giving investors a reference point for management's current expectations (Corporate guidance).Mise à jour du récit • Feb 10
OGN: Acquisition Interest And New Approvals Will Support A Rerated Earnings Profile
Analysts have revised their price targets on Organon. The updated view reflects changes in the discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations.Article d’analyse • Jan 29
The Market Lifts Organon & Co. (NYSE:OGN) Shares 25% But It Can Do More
Organon & Co. ( NYSE:OGN ) shares have continued their recent momentum with a 25% gain in the last month alone. Not all...Mise à jour du récit • Jan 26
OGN: Governance Reset And Policy Headwinds Will Shape A Steady Execution Path
Narrative update on Organon Analysts have trimmed their price target on Organon to US$9 from US$10, reflecting updated views on U.S. policy headwinds for Nexplanon, recent sales practice issues limited to that product, and softer expectations in the respiratory business that also feed into slightly lower discount rate and future P/E assumptions. Analyst Commentary Recent commentary focuses on how the updated guidance and product specific issues could affect Organon’s valuation, execution risk, and medium term growth profile.Mise à jour du récit • Jan 11
OGN: Governance Reset Around Nexplanon Controls Will Gradually Restore Market Confidence
Analysts have trimmed their price targets on Organon, with cuts such as US$10 to US$9 and US$18 to US$5. These changes reflect ongoing concerns about the Nexplanon related investigation, recent leadership changes, and updated revenue guidance.Mise à jour du récit • Dec 26
OGN Internal Control Failures Will Likely Drive Shares Toward Mid Single Digits
Analysts have sharply reduced their Organon price target to about $5 from roughly $9, citing downgraded ratings and heightened concerns over internal controls, Nexplanon related channel stuffing, and softer revenue guidance, which is being weighed down by U.S. policy headwinds and respiratory portfolio challenges. Analyst Commentary Bearish analysts are signaling a more cautious stance on Organon, reflecting heightened skepticism around the company’s execution, governance, and growth outlook.Mise à jour du récit • Dec 12
OGN: Governance Reset And New Leadership Will Restore Confidence Over Time
Analysts trimmed their price target on Organon by about one dollar to reflect a slightly lower fair value estimate, modestly higher perceived risk, and concerns over internal control breakdowns and Nexplanon-driven revenue headwinds. Analyst Commentary Recent Street research reflects a far more cautious stance on Organon, with reduced price targets and weaker ratings signaling diminished confidence in the company’s near term execution and growth trajectory.Mise à jour du récit • Nov 28
OGN: Leadership Changes And Governance Reforms Will Drive Renewed Confidence
Analysts have lowered their price target for Organon and now expect $9.67 per share, compared to the prior estimate of $10.33. The change is attributed to continued headwinds from internal control concerns and weaker revenue growth forecasts.Article d’analyse • Nov 14
Earnings Release: Here's Why Analysts Cut Their Organon & Co. (NYSE:OGN) Price Target To US$9.67
It's been a pretty great week for Organon & Co. ( NYSE:OGN ) shareholders, with its shares surging 14% to US$7.62 in...Mise à jour du récit • Nov 12
OGN: Internal Control Improvements Will Restore Confidence Amid Leadership Transition
Organon’s analyst price target was reduced from $10 to $9, as analysts cited concerns around internal controls, lowered revenue guidance, and lingering effects from recent leadership and business challenges. Analyst Commentary Recent Street research reflects a challenging outlook for Organon, with analysts closely scrutinizing both the company's fundamentals and the longer-term prospects following significant leadership changes and internal control issues.Article d’analyse • Nov 06
Investors Give Organon & Co. (NYSE:OGN) Shares A 41% Hiding
Organon & Co. ( NYSE:OGN ) shareholders won't be pleased to see that the share price has had a very rough month...Mise à jour du récit • Oct 27
Leadership Changes And Regulatory Concerns Will Shape Near-Term Market Prospects
Organon's analyst price target has dropped sharply from $13.17 to $10.83. Analysts cite lingering concerns about internal controls and leadership stability following recent executive changes and investigations.Mise à jour du récit • Aug 06
New Product Launches And Biosimilars Will Open Global Healthcare Markets
Despite improved revenue growth forecasts for Organon, a higher discount rate has outweighed these gains, resulting in a lower consensus price target from $13.33 to $12.60. What's in the News Organon raised full-year 2025 revenue guidance to $6.275–$6.375 billion and slightly improved its nominal revenue growth outlook.Article d’analyse • May 08
Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) 30% Share Price Plunge
To the annoyance of some shareholders, Organon & Co. ( NYSE:OGN ) shares are down a considerable 30% in the last month...Article d’analyse • May 04
Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02
Organon & Co. ( NYSE:OGN ) is reducing its dividend from last year's comparable payment to $0.02 on the 12th of June...Article d’analyse • Apr 28
Organon (NYSE:OGN) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Mar 24
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
With a price-to-earnings (or "P/E") ratio of 4.6x Organon & Co. ( NYSE:OGN ) may be sending very bullish signals at the...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$246m |
| Dec 31 2025 | US$6m | US$819k | US$187m |
| Sep 30 2025 | n/a | n/a | US$501m |
| Jun 30 2025 | n/a | n/a | US$700m |
| Mar 31 2025 | n/a | n/a | US$750m |
| Dec 31 2024 | US$4m | US$750k | US$864m |
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$4m | US$741k | US$1b |
| Sep 30 2023 | n/a | n/a | US$585m |
| Jun 30 2023 | n/a | n/a | US$754m |
| Mar 31 2023 | n/a | n/a | US$746m |
| Dec 31 2022 | US$3m | US$689k | US$917m |
Rémunération vs marché: La rémunération totale de Joe ($USD 5.77M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 6.98M ).
Rémunération et revenus: La rémunération de Joe a augmenté de plus de 20 % tandis que les bénéfices de l'entreprise ont chuté de plus de 20 % au cours de l'année écoulée.
PDG
Joe Morrissey (61 yo)
less than a year
Titularisation
US$5,772,848
Compensation
Mr. Joseph T. Morrissey, Jr. also known as Joe, served as Executive Vice President and Head of Manufacturing & Supply at Organon & Co. and served as its Head of Manufacturing since June 2, 2021 until Octob...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chair of the Board | 5.1yrs | US$460.65k | 0.030% $ 1.1m | |
| Chief Executive Officer | less than a year | US$5.77m | 0.047% $ 1.7m | |
| Executive VP & CFO | 5.1yrs | US$5.69m | 0.081% $ 2.9m | |
| Executive VP | 5.1yrs | US$3.55m | 0.044% $ 1.6m | |
| Executive VP | 3.5yrs | US$3.54m | 0.035% $ 1.3m | |
| Executive VP | 2.8yrs | US$3.82m | 0.011% $ 408.8k | |
| Head of Investor Relations | 5.5yrs | pas de données | pas de données | |
| Chief Strategy Officer & Head of Corporate Development | no data | pas de données | 0.026% $ 942.2k | |
| Executive VP & Chief Human Resources Officer | 5.1yrs | pas de données | 0.039% $ 1.4m | |
| Executive VP and Head of Enterprise Services & Solutions | 5.1yrs | pas de données | 0.027% $ 960.0k | |
| Head of Manufacturing & Supply | less than a year | pas de données | 0.013% $ 452.3k | |
| Head of International Commercial | 1.5yrs | pas de données | pas de données |
3.5yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: L'équipe de direction de OGN est considérée comme expérimentée (ancienneté moyenne 3.5 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chair of the Board | 5.1yrs | US$460.65k | 0.030% $ 1.1m | |
| Lead Independent Director | 5.1yrs | US$384.14k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$360.00k | 0.00024% $ 8.5k | |
| Independent Director | 5.1yrs | US$370.00k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$363.66k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$385.00k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$380.00k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$370.00k | 0% $ 0 | |
| Independent Director | 1yr | US$280.00k | 0.000040% $ 1.4k | |
| Independent Director | 5.1yrs | US$370.00k | 0% $ 0 |
5.1yrs
Durée moyenne de l'emploi
65.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de OGN sont considérés comme expérimentés (ancienneté moyenne 5.1 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/31 04:41 |
| Cours de l'action en fin de journée | 2026/07/31 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Organon & Co. est couverte par 14 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Jason Matthew Gerberry | BofA Global Research |